NCT04456023View on ClinicalTrials.gov

Study of Tisagenlecleucel in Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-cell Non-Hodgkin Lymphoma (DLBCL)

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

January 31, 2022

Primary Completion Date

October 31, 2022

Study Completion Date

September 27, 2027

Conditions
Diffuse Large B-Cell Lymphoma (DLBCL)
Interventions
BIOLOGICAL

Tisagenlecleucel

A single intravenous (i.v.) infusion of 0.6 - 6.0×10\^8 CAR positive viable T cells.

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY